Huang et al. also discover that in mouse breast cancer models, using a low dose of vascular normalization agent, anti-VEGFR2 antibodies, can increase CD4+ and CD8+ T cell infiltration, reprogram the tumor microenvironment, and enhance the efficacy of immunotherapy [384]. The gene discussed is CD4; the disease is neoplasm.